CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
종목 코드 CDNA
회사 이름CareDx Inc
상장일Jul 17, 2014
CEOMr. John W. Hanna
직원 수644
유형Ordinary Share
회계 연도 종료Jul 17
주소8000 Marina Blvd
도시BRISBANE
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호94005
전화14152872300
웹사이트https://www.caredx.com/
종목 코드 CDNA
상장일Jul 17, 2014
CEOMr. John W. Hanna
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음